EFFECT OF CLINICAL USE OF PROTON PUMP INHIBITORS ON SERUM LEVEL OF GASTRIN-17, PEPSINOGEN I, AND PEPSINOGEN II

(1) Digestive Disease Research Center, Medical Sciences, University of Tehran, Tehran, Iran (Islamic Republic of)

(2) Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

(3) Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States

(4) Lifestyle, Environment and Cancer Group, International Agency for Research on Cancer, Lyon, France

(5) Swedish Institute for Infectious Disease Control, Solna, Stockholm, Sweden



This item was part of the OESOPHAGEAL, GASTRIC AND DUODENAL DISORDERS II session at Gastro 2009 UEGW/WCOG London (17th UEGW)